Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac.

Junco JA, Rodríguez R, Fuentes F, Baladrón I, Castro MD, Calzada L, Valenzuela C, Bover E, Pimentel E, Basulto R, Arteaga N, Cid-Arregui A, Sariol F, González L, Porres-Fong L, Medina M, Rodríguez A, Garay AH, Reyes O, López M, de Quesada L, Alvarez A, Martínez C, Marrero M, Molero G, Guerra A, Rosales P, Capote C, Acosta S, Vela I, Arzuaga L, Campal A, Ruiz E, Rubio E, Cedeño P, Sánchez MC, Cardoso P, Morán R, Fernández Y, Campos M, Touduri H, Bacardi D, Feria I, Ramirez A, Cosme K, Saura PL, Quintana M, Muzio V, Bringas R, Ayala M, Mendoza M, Fernández LE, Carr A, Herrera L, Guillén G.

Front Oncol. 2019 Feb 25;9:49. doi: 10.3389/fonc.2019.00049. eCollection 2019.


Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.

Aguilar FF, Barranco JJ, Fuentes EB, Aguilera LC, Sáez YL, Santana MD, Vázquez EP, Baker RB, Acosta OR, Pérez HG, Nieto GG.

Vaccine. 2012 Oct 12;30(46):6595-9. doi: 10.1016/j.vaccine.2012.08.020. Epub 2012 Aug 23.


Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.

Barranco JA, Millar RP, Fuentes F, Bover E, Pimentel E, Basulto R, Calzada L, Morán R, Rodríguez A, Garay H, Reyes O, Castro MD, Bringas R, Arteaga N, Toudurí H, Rabassa M, Fernández Y, Serradelo A, Hernández E, Guillén GE.

Oncol Lett. 2016 Aug;12(2):963-970. Epub 2016 Jun 7.


Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer.

Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE, Bishop MC.

Br J Cancer. 2000 Aug;83(4):443-6.


Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

Hall MC, Fritzsch RJ, Sagalowsky AI, Ahrens A, Petty B, Roehrborn CG.

Urology. 1999 May;53(5):898-902; discussion 902-3.


Vaccines for control of fertility and hormone dependent cancers.

Talwar GP, Singh O, Pal R, Chatterjee N.

Int J Immunopharmacol. 1992 Apr;14(3):511-4. Review.


EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology.

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.


The influence of different peptide combinations to increase the immunogenicity of the Gonadotrophin Releasing Hormone Vaccine for prostate cancer treatment.

Aguilar FF, Barranco JJ, Aguilera LC, Fuentes EB, Serradelo Leal JA, López EH, Vázquez EP, Baker RB, Acosta OR, Pérez HG, Nieto GG.

J Exp Ther Oncol. 2017 Nov;12(2):87-94.


Gonadotrophin releasing hormone-based vaccine, an effective candidate for prostate cancer and other hormone-sensitive neoplasms.

Junco JA, Basalto R, Fuentes F, Bover E, Reyes O, Pimentel E, Calzada L, Castro MD, Arteaga N, López Y, Hernández H, Bringas R, Garay H, Peschke P, Bertot J, Guillén G.

Adv Exp Med Biol. 2008;617:581-7. doi: 10.1007/978-0-387-69080-3_60.


Plasmid DNA vaccine coding eight repeats of gonadotrophin-releasing hormone induced atrophy of prostate in male mice.

Rima UK, Bari ASM, Hossain MZ, Khan MAH.

Prostate Int. 2018 Dec;6(4):151-156. doi: 10.1016/j.prnil.2018.01.001. Epub 2018 Jan 12.


Effects of GnRH immunization in sexually mature pony stallions.

Turkstra JA, van der Meer FJ, Knaap J, Rottier PJ, Teerds KJ, Colenbrander B, Meloen RH.

Anim Reprod Sci. 2005 Apr;86(3-4):247-59.


Immunotherapy of prostate cancer in a murine model using a novel GnRH based vaccine candidate.

Junco JA, Peschke P, Zuna I, Ehemann V, Fuentes F, Bover E, Pimentel E, Basulto R, Reyes O, Calzada L, Castro MD, Arteaga N, López Y, Garay H, Hernández H, Bringas R, Guillén GE.

Vaccine. 2007 Dec 5;25(50):8460-8. Epub 2007 Oct 4.


Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.

Triozzi PL, Bolger GB, Neidhart J, Rinehart JJ, Saleh M, Allen KO, Sellers S, Waddell MJ.

Prostate. 2005 Dec 1;65(4):316-21.


Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial.

Caballero I, Aira LE, Lavastida A, Popa X, Rivero J, González J, Mesa M, González N, Coba K, Lorenzo-Luaces P, Wilkinson B, Santiesteban Y, Santiesteban Y, Troche M, Suarez E, Crombet T, Sánchez B, Casacó A, Macías A, Mazorra Z.

Front Pharmacol. 2017 May 10;8:263. doi: 10.3389/fphar.2017.00263. eCollection 2017.


Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.

Martínez-Piñeiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A; Triptocare Study Group.

BJU Int. 2014 Oct;114(4):608-16. doi: 10.1111/bju.12542. Epub 2014 Apr 4.


Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.

Pathak AS, Pacificar JS, Shapiro CE, Williams SG.

J Urol. 2007 Jun;177(6):2132-5; discussion 2135.


Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.

Wilke D, Patil N, Hollenhorst H, Bowes D, Rutledge R, Ago C.

Pharmacotherapy. 2018 Mar;38(3):327-333. doi: 10.1002/phar.2084. Epub 2018 Feb 7.


Supplemental Content

Support Center